Not independent
Tenure on this board
14.6 yrs
Meeting calendar
HROW · Annual meeting · Thursday, June 18, 2026
Harrow Inc
4 nominees · 3 ballot items.
Stockholders will vote to elect four directors, cast a non-binding advisory vote to approve named executive officer compensation, and ratify Deloitte & Touche LLP as the company’s independent registered public accounting firm for 2026.
Market cap
$1.7B
1Y TSR
+26.2%
Board grade
B-
Record date
Apr 21, 2026
Filing
DEF 14A
Meeting concluded · Jun 18, 2026
Follow how the vote landed and what changed on Harrow Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect four directors: Mark L. Baum, Adrienne L. Graves, Lauren P. Silvernail, and Perry J. Sternberg, each to serve until the 2027 Annual Meeting or until their successors are duly elected and qualified.
- 2
Advisory Vote on Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.
More detail
This advisory (non-binding) proposal asks stockholders to approve the overall compensation paid to the Company’s named executive officers as disclosed in the proxy. Management is seeking shareholder approval to validate its pay-for-performance approach, which includes substantial performance- and market-based equity awards (notably the 2025 PSUs with multi-year stock-price hurdles) and annual cash incentives tied to revenue, adjusted EBITDA and product performance. The vote does not change compensation directly but serves as a feedback mechanism for the Compensation Committee and the Board; a significant negative vote could prompt changes in future compensation design or disclosures. The Board recommends a vote FOR, arguing that the program aligns executive incentives with long-term stockholder value through a mix of short-term and long-term incentives, independent consultant benchmarking, and specific performance metrics. Contextually, the Company recently transitioned to large-accelerated filer reporting, expanded disclosures, and granted multi-year PSU awards to reinforce retention and align executives with sustained stock-price performance. Opponents of similar proposals often cite outsized CEO pay or complexity of equity vehicles; here, material elements driving perceived high pay include large multi-year PSU valuations tied to ambitious price hurdles. The Board’s justification emphasizes governance safeguards (independent Compensation Committee, consultant review, clawback policy) and that compensation outcomes reflected 2025 performance, including revenue growth and debt refinancing. Given the non-binding nature, the Board intends to consider shareholder feedback from the vote when setting future compensation but retains discretion over plan design and awards.
- 3
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot4
Independent
Tenure on this board
2.5 yrs
Also a director at
Ocular Therapeutix Inc (OCUL)Opus Genetics Inc (IRD)
Independent
Tenure on this board
1.6 yrs
Independent
Tenure on this board
4.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 7.6% | 2,832,230 | $100M |
| 2 | Private Capital Management, LLC | 4.2% | 1,562,000 | $55M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 1,403,056 | $49M |
| 4 | BlackRock, Inc. | 3.5% | 1,304,647 | $46M |
| 5 | Luxor Capital Group, LPActivist | 3.0% | 1,119,400 | $39M |
| 6 | BlackRock, Inc. | 2.5% | 948,542 | $33M |
| 7 | STATE STREET CORP | 2.3% | 855,047 | $30M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.0% | 738,498 | $26M |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1.5% | 548,327 | $19M |
| 10 | Ikarian Capital, LLC | 1.5% | 543,047 | $19M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Harrow Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Harrow Inc 2026 annual meeting?
- Harrow Inc (HROW) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.
- What is the record date for the Harrow Inc 2026 meeting?
- The record date for the Harrow Inc 2026 meeting is Tuesday, April 21, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Harrow Inc's 2026 meeting?
- The board is presenting 4 director nominees at the Harrow Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Harrow Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Harrow Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.